AstraZeneca : Calquence combination regimen demonstrated sta

a9173m

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

United Kingdom , China , Japan , Cambridge , Cambridgeshire , United States , Houston , Texas , Washington , America , Astrazeneca Calquence , Susan Galbraith , Adrian Kemp , Liud Acalabrutinib , Michael Wang , Md Anderson Cancer Center , Lymphoma Research Foundation , Commission File Number , Investor Relations Team , Gracell Biotechnologies Inc , Mantle Cell Lymphoma Program Of Excellence , Astrazeneca , National Organization For Rare Disorders , Nasdaq , Company Secretary , Health Database Study , Securities Exchange , Company On Social Media Astrazeneca , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Puddin Clarke Endowed Professor , Mantle Cell Lymphoma Program , Clinical Trials , Cancer Center , Executive Vice President , South America , Rare Diseases , Social Media , Mantle Cell , Accessed April , Combination With Acalabrutinib , Subjects With Previously Untreated , Increased Risk , Immunocompromised Individuals Despite Receipt , Retrospective Health Database Study , Markets ,